See other companies on Welcome to the Jungle
Nagi Bioscience
Alternative biological testing
- 1-20 employees
- B2B
- Biology
- SaaS
- Data Analysis
- Science
- Ecublens, VD
Jump to section
Company mission
To enable in vivo testing at the in vitro scale.
Our take
Animal testing has been a taboo topic for decades, but until this point has been the only way to reliably simulate humans. To mend this, Nagi Bioscience is developing alternative technology and data solutions to be able to pioneer "in vivo testing at the in vitro scale", which means doing live tests at the scale of lab dish or test tube testing.
To do so, the company has developed its own equipment, SydLab™ One, that allows ethical testing with small organisms at a scalable level to replace animal tests. It also offers software suites to analyse data from its machines, as well as data testing solutions and support and toxicology testing kits.
Boasting a team of scientists with extensive experience and knowledge in the research space, it is no surprise that Nagi Bioscience has produced such an exciting method. Having recently closed a large funding round, the company has set its sites to expand its impact in the drug discovery and toxicology testing market.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- A very innovative work environment where you can make a significant impact
- Access to unique technology and a compelling value proposition that sets us apart in the market
- A startup tailored package that includes an Employee Stock Ownership Plan (ESOP), providing an opportunity to share in our company’s success
- A dynamic and multi-disciplinary team of passionate professionals, sharing ideas and collectively driving innovation forward
Funding (last 2 of 5 rounds)
Oct 2023
$13.7m
SERIES A
Mar 2022
$2.6m
GRANT
Total funding: $18.5m
Leadership
Matteo Cornaglia
(CEO & Co-founder)Prior work includes Research And Teaching Assistant at EPFL (École polytechnique fédérale de Lausanne) and Visiting Researcher at KU Leuven.
Laurent Mouchiroud
(CSO & Co-founder)Also worked at EPFL (École polytechnique fédérale de Lausanne) through research projects including Aging and Drug Discovery as a Post Doctoral Scientist. Prior to this was a Visiting Scientist at UC Berkeley.